For gene therapy to work well, therapeutic molecules need to be efficiently delivered to the correct locations in the body — a job commonly given to adeno-associated viruses (AAV).
To improve the AAV’s ability to deliver therapeutics specifically to the lungs and airway, Mass General Brigham researchers developed and applied a new version, called AAV.CPP.16, that can be administered with a nasal spray. In preclinical models, the innovative tool outperformed previous versions by more…
Continue Reading
News Source: www.sciencedaily.com
Leave a Reply